STATEMENT OF WORK 3

Nurix Contract No. 7601

Nurix Therapeutics, Inc.	Mikrobiologicky ustav AV CR, v. v. i.	
Contact	Contact	
Phone	Phone	
Email	Email	
Project Title	Reference No.	

THE SERVICES SET FORTH IN THIS STATEMENT OF WORK ("SOW") dated as of November 22, 2022 (the "SOW Effective Date") shall be performed pursuant to the terms and conditions of that certain Master Services Agreement, dated as of June 15, 2022, by and between Nurix Therapeutics, Inc. ("Nurix") and Mikrobiologicky ustav AV CR, v. v. i. ("Company") (the "Agreement").

- 1. Services. Company shall render the hydrogen deuterium exchange services as outlined in the quotation attached document hereto (statement of work, proposal, work order, quote, or similar document) ("Attachment A") and other related services as agreed upon by the Parties (collectively, the "Services"). This cover page and the attached document together shall comprise the Statement of Work as defined in the Agreement.
- 2. Deliverables. Company shall provide all reports and other agreed-upon deliverables to be rendered in connection with the Services (collectively, the "*Deliverables*"), in a format mutually agreed to by both Parties. For clarity, Deliverables shall include, without limitation, analysis reports, data, heat maps, and completed structures.
- **3. Timelines.** All Services and Deliverables shall be provided in accordance with the timelines set forth in Attachment A, or if no timelines are included in Attachment A, as agreed to by the Parties.
- **4. Term.** Unless terminated earlier as provided in the Agreement, the term of this SOW shall begin on the SOW Effective Date and continue until the earlier of the completion of the Services or one (1) year following the SOW Effective Date.
- **5. Invoicing and Payments.** Company shall invoice Nurix for payment according to the estimated costs and payment schedules set forth in Attachment A. Payment shall be made within thirty (30) days of Nurix's receipt of a Valid Invoice sent by Company. A "*Valid*

Invoice" is an invoice that includes a purchase order ("*PO*") number provided to Company by Nurix. For clarity, payments made pursuant to invoices that do not include a PO number, may be subject to delay.

Company shall send invoices to Nurix at the following address:

Nurix Therapeutics, Inc. 1700 Owens Street, Suite 205 San Francisco, CA 94158 Attention: Accounts Payable Email: accountspayable@nurixtx.com

6. General Terms.

- **A. Capitalization.** Capitalized terms not otherwise defined herein shall have their respective meanings in the Agreement.
- **B.** Conflicts. In the event of a conflict between the terms of this SOW and the Agreement, the Agreement shall control. In the event of a conflict between the terms set forth in this SOW and any attachment hereto, the terms of this SOW shall control.

IN WITNESS WHEREOF, duly authorized representatives of the Parties have signed this SOW as of the SOW Effective Date.

Nurix Therapeutics, Inc.

Mikrobiologicky ustav AV CR, v. v. i.

By:		By:	
Name:	Christine Ring	Name:	Jiri Hasek
Title:	General Counsel	Title:	Director
Date:	November 21, 2022	Date:	November 22, 2022

ATTACHMENT A


A) Service:

- B) Shared Reagents:

C) Shared documents and information:



D) **Description of Service**:





-	
	-
	_

E) Deliverables:

The study results will be delivered as:



F) Compensation

The cost of the project in its full scope cannot exceed 400 000 CZK. Conversion rates to USD will be taken from the day of invoice issuance. Billing invoices will be based on the exact cost of experiments

that need to be conducted to reach the endpoints. An example of the cost structure for the proposed activities is attached.